Results 201 to 210 of about 115,103 (337)

Update on gastroesophageal reflux disease (GERD): diagnosis

open access: diamond, 2011
Aloísio Carvalhaes   +2 more
openalex   +1 more source

Validation of the PROMIS Global Physical and Mental Health Scale for Gastrointestinal Disorders: A Large‐Scale Cross‐Sectional Survey

open access: yesNeurogastroenterology &Motility, EarlyView.
The 4‐item revised version of the Hays model from the PROMIS Global Health Scale exhibits stronger psychometric properties than the original model. This ultra‐brief assessment tool is a reliable measure for evaluating quality of life in both gastrointestinal and non‐gastrointestinal cohorts.
Pragalathan Apputhurai   +5 more
wiley   +1 more source

Upper gastrointestinal tract scintigraphy and ultrasonography in diagnosis of gastroesophageal reflux in children.

open access: green, 2011
Bogumiła Elbl   +6 more
openalex   +1 more source

Gastroesophageal Reflux

open access: yesAnnals of Surgery, 1973
W S, Battle, L M, Nyhus, C T, Bombeck
openaire   +3 more sources

Sleep Bruxism Self‐Report and Awake Bruxism: An Ecological Momentary Assessment

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives The present study seeks to investigate the association between sleep bruxism (SB) and awake bruxism (AB) in healthy individuals, assessing whether self‐reported SB is associated with higher AB frequency through self‐report and Ecological Momentary Assessment (EMA).
Aurora Manfredini   +4 more
wiley   +1 more source

Clinical characteristics and risk factors of refractory gastroesophageal reflux disease: A multicenter cross-sectional study. [PDF]

open access: yesWorld J Gastroenterol
Zhang N   +31 more
europepmc   +1 more source

Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang   +3 more
wiley   +1 more source

Burdens of Gastroesophageal Reflux Disease in China: Findings from the 2021 GBD Study. [PDF]

open access: yesPLoS One
Liang Z   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy